Correlation Between Novo Nordisk and Onxeo SA

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Novo Nordisk and Onxeo SA at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novo Nordisk and Onxeo SA into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Novo Nordisk AS and Onxeo SA, you can compare the effects of market volatilities on Novo Nordisk and Onxeo SA and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novo Nordisk with a short position of Onxeo SA. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novo Nordisk and Onxeo SA.

Diversification Opportunities for Novo Nordisk and Onxeo SA

0.32
  Correlation Coefficient

Weak diversification

The 3 months correlation between Novo and Onxeo is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding Novo Nordisk AS and Onxeo SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Onxeo SA and Novo Nordisk is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novo Nordisk AS are associated (or correlated) with Onxeo SA. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Onxeo SA has no effect on the direction of Novo Nordisk i.e., Novo Nordisk and Onxeo SA go up and down completely randomly.

Pair Corralation between Novo Nordisk and Onxeo SA

Assuming the 90 days trading horizon Novo Nordisk AS is expected to under-perform the Onxeo SA. But the stock apears to be less risky and, when comparing its historical volatility, Novo Nordisk AS is 2.31 times less risky than Onxeo SA. The stock trades about -0.02 of its potential returns per unit of risk. The Onxeo SA is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  6.85  in Onxeo SA on September 22, 2024 and sell it today you would earn a total of  0.68  from holding Onxeo SA or generate 9.93% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy98.48%
ValuesDaily Returns

Novo Nordisk AS  vs.  Onxeo SA

 Performance 
       Timeline  
Novo Nordisk AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Novo Nordisk is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders.
Onxeo SA 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Onxeo SA are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Onxeo SA reported solid returns over the last few months and may actually be approaching a breakup point.

Novo Nordisk and Onxeo SA Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Novo Nordisk and Onxeo SA

The main advantage of trading using opposite Novo Nordisk and Onxeo SA positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novo Nordisk position performs unexpectedly, Onxeo SA can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onxeo SA will offset losses from the drop in Onxeo SA's long position.
The idea behind Novo Nordisk AS and Onxeo SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

Stocks Directory
Find actively traded stocks across global markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio